[1] Peiris M, Monteith GR, Roberts-Thomson SJ, Cabot PJ. A model of experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice for the characterisation of intervention therapies. J Neurosci Methods. 2007; 163(2): 245-254.
[2] Furlan R, Kurne A, Bergami A, Brambilla E, Maucci R, Gasparini L, Butti E, Comi G, Ongini E, Martino G. A nitric oxide releasing derivative of flurbiprofen inhibits experimental autoimmune encephalomyelitis. J Neuroimmunol. 2004; 150(1-2): 9-10.
[3] Bjartmar C, Trapp BD. Axonal degeneration and progressive neurologic disability in multiple sclerosis. Neurotox Res. 2003; 5(1-2):157-164.
[4] Prat A, Antel J. Pathogenesis of multiple sclerosis. Curr Opin Neurol. 2005; 18(3): 225-230.
[5] Becher B, Bechmann I, Greter M. Antigen presentation in autoimmunity and CNS inflammation: how T lymphocytes recognize the brain. J Mol Med (Berl). 2006; 84(7):532-543.
[6] Minagar A, Alexander JS. Blood-brain barrier disruption in multiple sclerosis. Mult Scler. 2003; 9(6): 540-549.
[7] Zaheer S, Wu Y, Bassett J, Yang B, Zaheer A. Glia maturation factor regulation of STAT expression: a novel mechanism in experimental autoimmune encephalomyelitis. Neurochem Res. 2007; 32(12): 2123-2131.
[8] Fisher AE, Maxwell SC, Naughton DP. Superoxide and hydrogen peroxide suppression by metal ions and their EDTA complexes. Biochem Biophys Res Commun. 2004; 316(1): 48-51.
[9] Hendriks JJ, Teunissen CE, de Vries HE, Dijkstra CD. Macrophages and neurodegeneration. Brain Res Brain Res Rev. 2005; 48(2): 185-195.
[10] Murphy AC, Lalor SJ, Lynch MA, Mills KH. Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis. Brain Behav Immun. 2010; 24(4): 641-651.
[11] Mirshafiey A, Kianiaslani M. Autoantigens and autoantibodies in multiple sclerosis. Iran J Allergy Asthma Immunol. 2013; 12(4): 292-303.
[12] Sriram S. Role of glial cells in innate immunity and their role in CNS demyelination. J Neuroimmunol. 2011; 239(1-2): 13-20.
[13] Benveniste EN, Sparacio SM, Norris JG, Grenett HE, Fuller GM. Induction and regulation of interleukin-6 gene expression in rat astrocytes. J Neuroimmunol. 1990; 30(2-3): 201-212.
[14] Banati RB, Gehrmann J, Schubert P, Kreutzberg GW. Cytotoxicity of microglia. Glia. 1993; 7(1): 111-118.
[15] Jiang HR, Al Rasebi Z, Mensah-Brown E, Shahin A, Xu D, Goodyear CS, Fukada SY, Liu FT, Liew FY, Lukic ML. Galectin-3 deficiency reduces the severity of experimental autoimmune encephalomyelitis. J Immunol. 2009; 182(2): 1167-1173.
[16] Bradley WG, Daroff RB, Fenichel GM, Jankovic JN. Neurology in clinical practices. 5th ed. London: Elsevier, 2008.
[17] Park SU, Park NI, Kim YK, Suh SY, Eom SH, Lee SY. Application of plant biotechnology in the medicinal plant, Rehmannia glutinosa. J Med Plants Res. 2009; 3(13): 1258-1263.
[18] Recio MC, Giner RM, Manez S, Rios JL. Structural considerations on the iridoids as anti-inflammatory agents. Planta Med. 1994; 60(3): 232-234.
[19] Monsef-Esfahani HR, Hajiaghaee R, Shahverdi AR, Khorramizadeh MR, Amini M. Flavonoids, cinnamic acid and phenyl propanoid from aerial parts of Scrophularia striata. Pharm Biol. 2010; 48(3): 333-336.
[20] Azadmehr A, Afshari A, Baradaran B, Hajiaghaee R, Rezazadeh S, Monsef-Esfahani H. Suppression of nitric oxide production in activated murine peritoneal macrophages in vitro and ex vivo by Scrophularia striata ethanolic extract. J Ethnopharmacol. 2009; 124(1): 166-169.
[21] Azadmehr A, Maliji G, Hajiaghaee R, Shahnazi M, Afaghi A. Inhibition of pro-inflammatory cytokines by ethyl acetate extract of Scrophularia striata. Trop J Pharm Res. 2012; 11(6): 893- 897.
[22] Azadmehr A, Sofiabadi M, Hajiaghaee R. Analgesic effect and immunomodulation response on pro-inflammatory cytokines production by Scrophularia megalantha extract. Trop J Pharm Res. 2013; 12(6): 935-939.
[23] Mosayebi G, Ghazavi A, Payani MA. The effect of vitamin D3 on the inhibition of experimental autoimmune encephalomyelitis in C57BL/6 mice. J Iran Univ Med Sci. 2006; 13(52): 189-196.
[25] McRae BL, Kennedy MK, Tan LJ, Dal Canto MC, Picha KS, Miller SD. Induction of active and adoptive relapsing experimental autoimmune encephalomyelitis (EAE) using an encephalitogenic epitope of proteolipid protein. J Neuroimmunol. 1992; 38(3): 229-240.
[26] Beck J, Rondot P, Catinot L, Falcoff E, Kirchner H, Wietzerbin J. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol Scand. 1988; 78(4): 318-323.
[27] Miller A, al-Sabbagh A, Santos LM, Das MP, Weiner HL. Epitopes of myelin basic protein that trigger TGF-beta release after oral tolerization are distinct from encephalitogenic epitopes and mediate epitope-driven bystander suppression. J Immunol. 1993; 151(12): 7307-7315.
[28] Azadmehr A, Hajiaghaee R, Afshari A, Amirghofran Z, Refieian-Kopaei M, Yousofi Darani H , Shirzad H. Evaluation of in vivo immune response activity and in vitro anti-cancer effect by Scrophularia megalantha. J Med Plants Res. 2011; 5(11): 2365-2368.
[29] Taupin V, Renno T, Bourbonniere L, Peterson AC, Rodriguez M, Owens T. Increased severity of experimental autoimmune encephalomyelitis, chronic macrophage/microglial reactivity, and demyelination in transgenic mice producing tumor necrosis factor-alpha in the central nervous system. Eur J Immunol. 1997; 27(4): 905-913.
[30] Chen JQ, Brown TR, Russo J. Regulation of energy metabolism pathways by estrogens and estrogenic chemicals and potential implications in obesity associated with increased exposure to endocrine disruptors. Biochim Biophys Acta. 2009; 1793(7): 1128-1143.
[31] Jacobs CA, Baker PE, Roux ER, Picha KS, Toivola B, Waugh S, Kennedy MK. Experimental autoimmune encephalomyelitis is exacerbated by IL-1 alpha and suppressed by soluble IL-1 receptor. J Immunol. 1991; 146(9): 2983-2989.
[32] Okuda Y, Sakoda S, Fujimura H, Saeki Y, Kishimoto T, Yanagihara T. IL-6 plays a crucial role in the induction phase of myelin oligodendrocyte glucoprotein 35-55 induced experimental autoimmune encephalomyelitis. J Neuroimmunol. 1999; 101(2): 188-196.
[33] Tran EH, Prince EN, Owens T. IFN-gamma shapes immune invasion of the central nervous system via regulation of chemokines. J Immunol. 2000; 164(5): 2759-2768.
[34] Xiao BG, Ma CG, Xu LY, Link H, Lu CZ. IL-12/IFN-gamma/NO axis plays critical role in development of Th1-mediated experimental autoimmune encephalomyelitis. Mol Immunol. 2008; 45(4): 1191-1196.
[35] Rieks M, Hoffmann V, Aktas O, Juschka M, Spitzer I, Brune N, Schimrigk S, Przuntek H, Pohlau D. Induction of apoptosis of CD4+ T cells by immunomodulatory therapy of multiple sclerosis with glatiramer acetate. Eur Neurol. 2003; 50(4): 200-206.
[36] Yong VW, Chabot S, Stuve O, Williams G. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology. 1998; 51(3): 682-689.
[39] Jadidi-Niaragh F, Mirshafiey A. Th17 cell, the new player of neuroinflammatory process in multiple sclerosis. Scand J Immunol. 2011; 74(1): 1-13.
[40] Dalla Libera D, Di Mitri D, Bergami A, Centonze D, Gasperini C, Grasso MG, Galgani S, Martinelli V, Comi G, Avolio C, Martino G, Borsellino G, Sallusto F, Battistini L, Furlan R. T regulatory cells are markers of disease activity in multiple sclerosis patients. PLoS One. 2011; Article ID e21386.
[41] Gu Y, Yang J, Ouyang X, Liu W, Li H, Yang J, Bromberg J, Chen SH, Mayer L, Unkeless JC, Xiong H. Interleukin 10 suppresses Th17 cytokines secreted by macrophages and T cells. Eur J Immunol. 2008; 38(7): 1807-1813.